Experts Reaffirm Safety of Tylenol During Pregnancy Amid Confusion

President Donald Trump sparked concern last year when he suggested that the use of Tylenol during pregnancy could be linked to an increased risk of autism. This statement led to a surge of inquiries among patients, particularly at the office of Dr. Nathaniel DeNicola, an obstetrician-gynecologist based in Newport Beach, California. However, the initial wave of confusion subsided within a week, as the medical community swiftly addressed the claims.

Dr. DeNicola, who contributed to the guidance from the American College of Obstetricians and Gynecologists (ACOG) regarding acetaminophen use in pregnancy, noted that the response from medical experts was decisive and reassuring. He stated, “The public seems to have taken the direction from the experts, that they trust their voice on this.”

In the months following Trump’s remarks, Dr. Lynn Yee, a maternal-fetal medicine physician at Northwestern University Feinberg School of Medicine, observed a decline in her patients’ concerns about Tylenol. She remarked that while there was considerable anxiety in late 2022, by early 2023, fewer patients were asking questions about acetaminophen. Dr. Yee credited professional organizations for their effective communication on the safety of the medication, emphasizing the importance of consulting healthcare providers.

The medical community has consistently highlighted that autism’s causes are multifactorial, with factors such as genetics, parental age, and environmental exposures playing significant roles. While some studies have suggested a potential link between acetaminophen and neurodevelopmental disorders, the overall evidence remains inconclusive. In its guidance released after Trump’s comments, ACOG reiterated that “acetaminophen remains the analgesic and antipyretic of choice during pregnancy,” recommending its use at the lowest effective dose for the shortest duration.

Acetaminophen, known as paracetamol in some regions, is regarded as the only safe over-the-counter option for pain relief during pregnancy. Other medications, such as ibuprofen and aspirin, present risks that could lead to serious complications. Medical professionals frequently recommend Tylenol to manage pain or fever, as untreated fevers can pose significant health risks to both the mother and the fetus, potentially leading to miscarriage or neurodevelopmental disorders.

The discourse surrounding Tylenol took a political turn when the White House released a fact sheet in September 2022, referencing studies that suggested a correlation between acetaminophen use during pregnancy and neurological effects in children. Subsequently, the US Food and Drug Administration advised clinicians to consider minimizing acetaminophen use for routine low-grade fevers during pregnancy.

One of the studies cited by the Trump administration was an analysis of 46 previous studies, published in BMC Environmental Health. The senior author, Dr. Andrea Baccarelli, dean of the faculty at the Harvard T.H. Chan School of Public Health, stated that the association between acetaminophen and neurodevelopmental disorders appeared strongest with prolonged use. Baccarelli emphasized the importance of balancing the need for pain relief with potential risks, advocating for the lowest effective dose.

Recent research published in The Lancet Obstetrics, Gynaecology & Women’s Health provided new insights, finding no evidence that acetaminophen use during pregnancy increases the risk of autism or related conditions. This study reviewed 43 published studies involving over 300,000 pregnancies, of which 17 were included in a meta-analysis.

Lead author Dr. Asma Khalil, a consultant obstetrician at St George’s Hospital in London, expressed that the findings would provide reassurance to pregnant women. The US Department of Health and Human Services acknowledged that the new research does not definitively resolve questions surrounding Tylenol’s risks but noted its systematic evaluation of the existing studies.

Dr. Khalil responded to concerns about the study’s limitations, stating that it aimed to minimize biases by focusing on the most rigorous research methodologies. She maintained that the findings support the current clinical guidance that acetaminophen remains an appropriate treatment for pain and fever in pregnancy.

The analysis included data from sibling comparisons, which accounted for shared familial factors that could influence autism risk. This design was praised by Dr. Steven Kapp, a senior lecturer in psychology at the University of Portsmouth, who highlighted the study’s scientific rigor. He noted that sibling comparisons help clarify whether the medication itself contributes to developmental disabilities.

While Dr. DeNicola applauded the new research, he acknowledged the limited number of sibling studies available and the need for more comprehensive data. He affirmed that the collective evidence offers reassurance regarding the therapeutic benefits of Tylenol without unfounded risks.

Dr. Baccarelli and his colleagues had previously indicated that while sibling comparisons help control certain confounding factors, they also have limitations that could affect interpretation. Nonetheless, Dr. Khalil asserted that sibling comparison studies represent some of the best designs for understanding the complexities of autism risk.

The new research emerged in response to heightened anxiety among pregnant patients regarding acetaminophen, particularly following Trump’s comments. Dr. Khalil noted the quick responses from national and international medical organizations, which aimed to reassure pregnant women about the safety of acetaminophen when used appropriately.

As the debate continues, experts emphasize the importance of informed decision-making in the context of pregnancy and the need for ongoing research to clarify the relationship between acetaminophen and neurodevelopmental outcomes.